Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
Authors
Keywords
-
Journal
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume -, Issue -, Pages 107815521879985
Publisher
SAGE Publications
Online
2018-09-26
DOI
10.1177/1078155218799850
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Temozolomide Combined with Radiotherapy in the Treatment of Recurrent Cranial Meningioma Previously Treated with Multiple Surgical Resections and Two Sessions of Radiosurgery: A Case Report and Literature Review
- (2018) Marta Scorsetti et al. TUMORI
- Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
- (2017) Thomas Graillon et al. Oncotarget
- A phase II trial of PTK-787 (PTK/ZK) in recurrent or progressive meningiomas
- (2017) R. DeBoer et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic therapy for recurrent meningioma
- (2016) E. Le Rhun et al. Expert Review of Neurotherapeutics
- A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
- (2016) Kent C. Shih et al. JOURNAL OF NEURO-ONCOLOGY
- Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies
- (2016) Michael Karsy et al. World Neurosurgery
- Systemic therapy for recurrent meningioma
- (2016) E. Le Rhun et al. Expert Review of Neurotherapeutics
- Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
- (2015) Elena Mazza et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005
- (2015) Yongli Ji et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab
- (2015) K. Ina Ly et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas
- (2015) K. Gerster-Gillieron et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin Receptor-Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial
- (2015) N. Marincek et al. JOURNAL OF NUCLEAR MEDICINE
- Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
- (2015) Julia Furtner et al. NEURO-ONCOLOGY
- Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy
- (2014) Marta Simó et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas
- (2014) Jeffrey J. Raizer et al. JOURNAL OF NEURO-ONCOLOGY
- Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
- (2014) T. Kaley et al. NEURO-ONCOLOGY
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
- (2014) Thomas J. Kaley et al. NEURO-ONCOLOGY
- Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
- (2014) A. D. Norden et al. NEUROLOGY
- Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor–directed therapy
- (2013) Jack Hou et al. Neurosurgical Focus
- Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients
- (2013) Fabio P. Nunes et al. PLoS One
- Antiangiogenic Agents for Nonmalignant Brain Tumors
- (2013) Joshua Rubin et al. Journal of Neurological Surgery Part B-Skull Base
- Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
- (2012) David A. Reardon et al. CANCER
- Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches
- (2012) Matthias Preusser et al. CLINICAL NEUROPATHOLOGY
- Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
- (2012) Emil Lou et al. JOURNAL OF NEURO-ONCOLOGY
- Atypical and anaplastic meningiomas treated with bevacizumab
- (2012) Lakshmi Nayak et al. JOURNAL OF NEURO-ONCOLOGY
- Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab
- (2011) S. Goutagny et al. ANNALS OF ONCOLOGY
- Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema
- (2011) DAMOUN NASSEHI et al. APMIS
- Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma
- (2011) Marc C. Chamberlain JOURNAL OF NEURO-ONCOLOGY
- Bevacizumab-induced regression of anaplastic meningioma
- (2010) M. J. A. Puchner et al. ANNALS OF ONCOLOGY
- Aberrant signaling pathways in meningiomas
- (2010) Brian T. Ragel et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
- (2009) Andrew D. Norden et al. JOURNAL OF NEURO-ONCOLOGY
- Interferon-α for recurrent World Health Organization grade 1 intracranial meningiomas
- (2008) Marc C. Chamberlain et al. CANCER
- Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas
- (2008) Alexandros Theodoros Panagopoulos et al. JOURNAL OF NEURO-ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started